<DOC>
	<DOCNO>NCT03001622</DOCNO>
	<brief_summary>The trial enroll patient moderate severe Hidradenitis Suppurativa ( HS ) . The primary goal trial evaluate safety tolerability IFX-1 administer 8 week patient . In addition trial aim characterize pharmacokinetics pharmacodynamics IFX-1 well generate preliminary data efficacy IFX-1 clinical endpoint ( e.g. , Hidradenitis Suppurativa Clinical Response ( HiSCR ) , Dermatology Life Quality Index ( DLQI ) , Visual Analog Scale ( VAS ) disease , VAS pain , Hidradenitis Suppurativa - Physician 's Global Assessment ( HS-PGA ) , Modified Sartorius Score ( mSS ) ) .</brief_summary>
	<brief_title>Studying Complement Inhibition Patients With Moderate Severe Hidradenitis Suppurativa</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year old 2 . Written inform consent 3 . Diagnosis HS least 1 year 4 . Hidradenitis suppurativa ( HS ) lesion least 2 distinct anatomic area , one Hurley Stage II III 5 . Total AN ( abscess nodule ) count ≥3 6 . Patients either primary secondary failure biological treatment eligible treatment biologicals 7 . Failure previous antimicrobial treatment 1 . Body weight 150 kg body weight 60 kg 2 . Has drain fistula count great 30 baseline 3 . Surgical management plan within next 24 week 4 . Occurrence flareup HS lead intravenous antimicrobial treatment within last 14 day 5 . Any disease condition likely interfere evaluation study product , outcome assessment satisfactory conduct study 1 . Active infection 2 . Severe congestive heart failure ( i.e. , New York Heart Association ( NYHA ) Class IV ) 3 . Depression 4 . History systemic lupus erythematosus rheumatoid arthritis 5 . Any immunodeficiency disease 6 . Active hematological solid malignant tumor 7 . Patients must active skin disease condition ( e.g. , bacterial , fungal , viral infection ) may interfere assessment HS . 6 . One follow abnormal laboratory result 1 . White blood cell count &lt; 2,500/mm3 2 . Neutrophil count &lt; 1000/mm3 3 . Serum Creatinine &gt; 3 x Upper Normal Limit ( UNL ) 4 . Total Bilirubin &gt; 2 x UNL 5 . AlanineAminotransferase ( ALAT ) &gt; 2 x UNL 6 . Positive screen test Hepatitis B , Hepatitis C , HIV 1/2 7 . Prior administration biological compound last 3 month 8 . Intake corticosteroid define daily intake prednisone equivalent 1 mg/kg last three week ; 9 . Intake Immunosuppressive drug within past 30 day ( e.g. , cyclosporine , tacrolimus ) 10 . General exclusion criterion 1 . Pregnant ( woman childbearing potential urine pregnancy test perform ) breastfeed woman 2 . Women childbearing potential ( define within two year last menstruation ) willing practice appropriate contraceptive measure ( e.g. , implanon , injection , oral contraceptive , intrauterine device , partner vasectomy , abstinence ) participate trial 3 . Participation interventional clinical trial within last three month 4 . Known intravenous drug abuse 5 . Employee study site , spouse/partner relative study staff ( e.g. , investigator , subinvestigators , study nurse ) relationship sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>